Rosa Ruiz-Valderas

Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis

Luís F. López‐Cortés, Rosa Ruiz-Valderas, Pompeyo Viciana et al. · Clinical Pharmacokinetics · 2002 · 230 citations

Medicine, Pharmacokinetics, Pharmacology +12

Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.

Luís F. López‐Cortés, M. T. Pastor-Ramos, Rosa Ruiz-Valderas et al. · PubMed · 2001 · 51 citations

Medicine, Ophthalmology, Pharmacology +16

Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermidis

Juan Domínguez-Herrera, Fernando Docobo-Pérez, Rafael López-Rojas et al. · Antimicrobial Agents and Chemotherapy · 2011 · 41 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen

Luís F. López‐Cortés, Rosa Ruiz-Valderas, Josefa Ruiz‐Morales et al. · Journal of Antimicrobial Chemotherapy · 2006 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations.

Luís F. López‐Cortés, Rosa Ruiz-Valderas, Ana Marín‐Niebla et al. · PubMed · 2005 · 27 citations

Pharmacy, Pharmacokinetics, Pharmacology +13